Although direct in vivo evidence linking SPD-mediated polyamination to tau pathology is limited, elevated SPD levels in AD brains and dysregulated polyamine pathways in tauopathy models suggest a potential biological role. The gene discussed is MAPT; the disease is Alzheimer disease.